

# Expert recommendations on the management of hypermetastatic cervical cancer receiving bevacizumab in the UK

British Journal of Cancer

121, 109-116

DOI: [10.1038/s41416-019-0481-y](https://doi.org/10.1038/s41416-019-0481-y)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Synthesis of a functionalized dipeptide for targeted delivery and pH-sensitive release of chemotherapeutics. Chemical Communications, 2020, 56, 285-288.	4.1	12
2	Randomized Phase 0/I Trial of the Mitochondrial Inhibitor ME-344 or Placebo Added to Bevacizumab in Early HER2-Negative Breast Cancer. Clinical Cancer Research, 2020, 26, 35-45.	7.0	22
3	Therapeutic options following second-line platinum-based chemotherapy in patients with recurrent ovarian cancer: Comparison of active surveillance and maintenance treatment. Cancer Treatment Reviews, 2020, 90, 102107.	7.7	21
4	2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension, 2020, 75, 1334-1357.	2.7	1,895
5	2020 International Society of Hypertension global hypertension practice guidelines. Journal of Hypertension, 2020, 38, 982-1004.	0.5	452
6	Exploiting the folate receptor $\alpha$ in oncology. Nature Reviews Clinical Oncology, 2020, 17, 349-359.	27.6	262
7	Angiogenesis in gynecological cancers and the options for anti-angiogenesis therapy. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1875, 188446.	7.4	41
8	Investigation of drugs affecting hypertension in bevacizumab-treated patients and examination of the impact on the therapeutic effect. Cancer Medicine, 2021, 10, 164-172.	2.8	10
9	Risk Stratification and Management of Arterial Hypertension and Cardiovascular Adverse Events Related to Cancer Treatments: An Oncology Network from Piedmont and Aosta Valley (North-Western) Tj ETQq0 00gBT /Overlock 10	0.9	1
10	Onco-hypertension: Overview of hypertension with anti-cancer agents. Journal of Onco-Nephrology, 2021, 5, 57-69.	0.6	8
11	Cisplatin plus paclitaxel chemotherapy with or without bevacizumab in postmenopausal women with previously untreated advanced cervical cancer: a retrospective study. BMC Cancer, 2021, 21, 133.	2.6	7
12	Effect of Metabolic Syndrome and Individual Components on Colon Cancer Characteristics and Prognosis. Frontiers in Oncology, 2021, 11, 631257.	2.8	6
13	Etiology and management of hypertension in patients with cancer. Cardio-Oncology, 2021, 7, 14.	1.7	27
14	Anlotinib: A Novel Targeted Drug for Bone and Soft Tissue Sarcoma. Frontiers in Oncology, 2021, 11, 664853.	2.8	44
15	Associations between initiating antihypertensive regimens on stage Iâ€”III colorectal cancer outcomes: A Medicare SEER cohort analysis. Cancer Medicine, 2021, 10, 5347-5357.	2.8	7
16	Peri-radiosurgical administration of bevacizumab improves radiographic response to single and fractionated stereotactic radiosurgery for large brain metastasis. Journal of Neuro-Oncology, 2021, 153, 455-465.	2.9	1
17	Real-World Experience of Bevacizumab as First-Line Treatment for Ovarian Cancer: The GINECO ENCOURAGE Cohort of 468 French Patients. Frontiers in Pharmacology, 2021, 12, 711813.	3.5	9
18	Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. European Heart Journal, 2022, 43, 280-299.	2.2	213

#	ARTICLE	IF	CITATIONS
19	The Meta-Analysis of Bevacizumab Combined with Platinum-Based Treatment of Malignant Pleural Effusions by Thoracic Perfusion. Journal of Oncology, 2022, 2022, 1-13.	1.3	5
20	VEGF Receptor Inhibitor-Induced Hypertension: Emerging Mechanisms and Clinical Implications. Current Oncology Reports, 2022, 24, 463-474.	4.0	28
21	Onco-hypertension: An Emerging Specialty. Advances in Chronic Kidney Disease, 2021, 28, 477-489.e1.	1.4	11
22	Dual sEH/COX-2 Inhibition Using PTUPBâ€”A Promising Approach to Antiangiogenesis-Induced Nephrotoxicity. Frontiers in Pharmacology, 2021, 12, 744776.	3.5	4
23	Pre-existing hypertension is associated with poor progression-free survival in newly diagnosed multiple myeloma patients. Journal of Thrombosis and Thrombolysis, 2022, , 1.	2.1	0
24	Cardiotoxicity of Biological Therapies in Cancer Patients: An In-depth Review. Current Cardiology Reviews, 2023, 19, .	1.5	3
25	Advances in Research on VEGF Pathway Inhibitors Related Renal Injury. Advances in Clinical Medicine, 2022, 12, 7462-7472.	0.0	0
27	Cancer Treatment-Related Cardiovascular Toxicity in GynecologicÂ—Malignancies. JACC: CardioOncology, 2023, 5, 159-173.	4.0	4
28	Machine Learning Application Identifies Germline Markers of Hypertension in Patients With Ovarian Cancer Treated With Carboplatin, Taxane, and Bevacizumab. Clinical Pharmacology and Therapeutics, 2023, 114, 652-663.	4.7	1
29	Targeted drug conjugate systems for ovarian cancer chemotherapy. Biomedicine and Pharmacotherapy, 2023, 165, 115151.	5.6	2
30	Management of hypertension in patients with cancer: challenges and considerations. CKJ: Clinical Kidney Journal, 2023, 16, 2336-2348.	2.9	2
31	<b><b>The Effects of Drug Exposure and SNPs on Aaptinib-induced Severe Toxicities in Solid Tumors</b></b>. Drug Metabolism and Disposition, 0, , DMD-AR-2023-001428.	3.3	1
32	Onco-Hypertension: Anticancer Therapy-Associated Hypertension. , 2024, , 456-465.		0
34	A new perspective in the prevention and treatment of antitumor therapy-related cardiotoxicity: Intestinal microecology. Biomedicine and Pharmacotherapy, 2024, 170, 115588.	5.6	1
35	Case report: Successful treatment of a patient undergoing haemodialysis with multifocal hepatocellular carcinoma using atezolizumab and bevacizumab. Frontiers in Oncology, 0, 13, .	2.8	1
36	Heartbreaker: Detection and prevention of cardiotoxicity in hematological malignancies. Blood Reviews, 2023, , 101166.	5.7	0
37	Safety of bevacizumab and olaparib as frontline maintenance therapy in advanced ovarian cancer: expert review for clinical practice. Frontiers in Oncology, 0, 13, .	2.8	0
38	Germline predictors for bevacizumab induced hypertensive crisis in ECOG-ACRIN 5103 and BEATRICE. British Journal of Cancer, 2024, 130, 1348-1355.	6.4	0